Phenol
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Phenol: From an Unrecorded Original Indication to Acrodermatitis Chronica Atrophicans
One-Sentence Summary
Phenol is a long-established antiseptic and protein-denaturing chemical. In South Africa it is registered in one product, a syrup, and the record does not state an approved indication. The TxGNN model predicts it may be relevant to acrodermatitis chronica atrophicans (late-stage Lyme borreliosis of the skin). There are 0 clinical trials and 0 publications supporting this direction, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Acrodermatitis chronica atrophicans |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available, and no original indication is recorded in the SAHPRA registration data. Phenol is known in general terms for antiseptic and protein-denaturing action. No mechanistic link to the predicted disease is documented.
Acrodermatitis chronica atrophicans is a late-stage skin manifestation of Lyme borreliosis and is treated with antibiotics. Phenol has no documented role in this condition. The very high score of 99.95% most likely reflects proximity in the knowledge graph rather than therapeutic evidence.
Phenol is also a corrosive and toxic agent. Any new use would need to be weighed against that hazard.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. G2011 (OM) | Biohist | Syrup | Not stated in the registration record |
Essential Medicines List (EML) status could not be determined from the available data.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials, literature or mechanistic rationale, and phenol’s toxicity profile argues against speculative new uses. The safety data required for even a first screening step are missing.
Among the other model-predicted indications, only acne keloid has any indirect signal. It is graded L4 and marked as a research question. That signal comes from published reports on modified phenol chemical peels for acne scars (PMID 17204096). It is not evidence for acne keloidalis itself, and the peels carry cardiac, hepatic, renal and pigmentary risks.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications), which is currently a blocking gap
- Mechanism of action data, for example from DrugBank
- The original approved indication of the Biohist syrup registration
- Any clinical or preclinical study of phenol in the predicted condition, before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.